Smith & Nephew PLC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NYSE
Cevian Capital II GP Limited has increased its beneficial ownership of Smith & Nephew plc ordinary shares to 14.18%, acquiring an additional 119,179,419 shares for approximately $1.67 billion.
NYSE
Cevian Capital II GP Limited has increased its beneficial ownership in Smith & Nephew plc to 13.09% through recent open market share purchases.
NYSE
Cevian Capital II GP Ltd has increased its beneficial ownership of Smith & Nephew plc ordinary shares to 11.88%, acquiring over 101 million shares for approximately $1.4 billion.
NYSE
Cevian Capital II GP Ltd has increased its beneficial ownership of Smith & Nephew plc shares to 10.71%, acquiring over 91 million shares for approximately $1.29 billion.
NYSE
Cevian Capital II GP LTD has increased its beneficial ownership in Smith & Nephew plc to 9.6% through recent share purchases totaling over $1 billion.
NYSE
Cevian Capital II GP Limited has significantly increased its beneficial ownership in medical technology firm Smith & Nephew PLC, now holding 8.50% of outstanding shares with an aggregate investment exceeding $1 billion.
NYSE
SCHEDULE 13D/A: Cevian Capital II GP Boosts Stake in Smith & Nephew PLC to 7.49%
Cevian Capital II GP Limited has increased its beneficial ownership in medical technology firm Smith & Nephew PLC to 7.49% of outstanding ordinary shares, representing an aggregate investment of approximately $815 million.